



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/601,029	07/26/2000	PETER HIMMELSBACH	BEIERSDORF-6	5165
27384	7590	10/28/2005	EXAMINER	
NORRIS, MCLAUGHLIN & MARCUS, PA 875 THIRD AVENUE 18TH FLOOR NEW YORK, NY 10022			PIERCE, JEREMY R	
			ART UNIT	PAPER NUMBER
			1771	

DATE MAILED: 10/28/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No.

09/601,029

Applicant(s)

HIMMELSBACH ET AL.

Examiner

Jeremy R. Pierce

Art Unit

1771

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 25 August 2005.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1,2,4-8,10-15 and 17-36 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1,2,4-8,10-15 and 17-36 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some \* c) ☐ None of:
1. ☒ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                   | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

## **DETAILED ACTION**

### ***Continued Examination Under 37 CFR 1.114***

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on June 30, 2005 has been entered.

### ***Response to Amendment***

2. Applicant's amendment filed on June 30, 2005 has been entered. Claims 1, 2, 6, and 11 have been amended. Claims 1, 2, 4-8, 10-15, and 17-36 are currently pending.

### ***Claim Rejections - 35 USC § 103***

3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

4. Claims 1, 4, 5, 7, 8, 10-15, 17, 18, 20-30, and 33-36 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lucast et al. (U.S. Patent No. 6,479,073) in view of

Art Unit: 1771

Merkle et al. (U.S. Patent No. 5,527,536) and Lucast et al. (U.S. Patent No. 5,407,717), and further in view of Koketsu et al. (U.S. Patent No. 5,547,223).

First regarding the new limitation that the yarns have a water absorption of less than 30%, Lucast et al. teach the backing layer fabric can be made of nylon (column 3, lines 32-34). Nylon is a synthetic material known to absorb water at a rate less than 30%. This is shown, for instance, at <http://www.sdplastics.com/nylon.html>, which states:

**Moisture absorption by nylon has been a source of great study for many years. Although all polymers absorb some amount of moisture, on none does it have such a significant effect as on nylons. Table 6.1 illustrates the moisture absorption levels of various types of nylons. (Ref 16)**

**Table 6.1 Absorption of Moisture by Nylons by Weight % at 50% R.H. and Saturation @ 23°C (Ref 16)**

Type of Nylon	Equilibrium @ 50% R.H.	Equilibrium @ Saturation
6	2.7	9.5
6/6	2.5	8.0
6/10	1.5	3.5
6/12	1.3	3.0
11	0.8	1.9
12	0.7	1.4

Applicant's specification also lists polyamide as a viable option for use in the present invention (page 9, line 27). Therefore, Lucast et al. meet the newly claimed limitation for water absorption.

Art Unit: 1771

Lucast et al. disclose a medical tape for use on human skin (column 1, lines 5-20). Lucast et al. teach the substrate layer for the tape may be a nonwoven fabric including stitch-bonded fabrics (column 3, line 2). The adhesive composition may comprise a styrene block copolymer (column 4, lines 17-21).

Lucast et al. do not teach a pharmacologically active agent to be present in the adhesive composition. Merkle et al. disclose a medical patch for controlled release of pharmacologically active agents (Abstract). The adhesive comprises a block copolymer that comprises polystyrene for one block and a mixture of ethylene and butylenes for another block (Abstract). It would have been obvious to a person having ordinary skill in the art at the time of the invention to incorporate a pharmacologically active agent into the tape of Lucast et al. in order to provide the tape with an enhanced medical function, as taught by Merkle et al.

Lucast et al. do not teach sterilizing the adhesive composition. The '717 Patent teaches that adhesive tapes that are used on human skin must be sterilized (column 11, lines 5-10). It would have been obvious to a person having ordinary skill in the art at the time of the invention to sterilize the Lucast et al. tape in order to make it safe for use on human skin, as taught by the '717 Patent.

With regard to claims 1, 21, and 22, Lucast et al. do not disclose how many stitches are present on backing layer of a stitch-bonded fabric per centimeter. Koketsu et al. teach the number of stitches in the backing layer would be a result effective variable that would alter the strength of the web, with more stitches supplying a stronger web (column 7, lines 16-32). It would have been obvious to one having ordinary skill in

Art Unit: 1771

the art to provide 5 to 50 longitudinal stitches per centimeter in order to create a stitch-bonded fabric with a desired strength and rigidity provided by the stitches, since it has been held that discovering an optimum value of a result effective variable involves only routine skill in the art. *In re Boesch*, 617 F.2d 272, 205 USPQ 215 (CCPA 1980).

With regard to claim 7, the backing material of Lucast et al. would be tearable by hand because it is used as medical tape. With regard to claims 8 and 24, Merkle et al. disclose the active substance is present in an amount between 2.5 and 25% by weight (Abstract). With regard to claim 11, Lucast et al. disclose using foaming agents in the adhesive (column 5, line 19). With regard to claim 12, Lucast et al. teach the adhesive may be discontinuously coated to the backing material (column 1, line 48). With regard to claims 13 and 35, Merkle et al. teach applying the adhesive by spraying (column 5, lines 1), but the limitation of the adhesive being sprayed on (for continuous coatings) or printed on (for discontinuous coatings) is a processing limitation that would not materially alter the claimed product. With regard to claim 14, Lucast et al. teach applying adhesive in a dot pattern (column 10, line 62). With regard to claims 17 and 18, Lucast et al. disclose the backing incorporate a low adhesion backside layer opposite the side where adhesive is located (column 3, lines 11-18). This layer would also cover the backing material according to claim 20. With regard to claim 33, Lucast et al. disclose the adhesive may comprise up to 20% of polymer material that is not a copolymer (column 4, lines 35-42). With regard to claim 34, Lucast et al. disclose using polyisoprene as a possible block polymer with polystyrene (column 4, lines 35-43). With

Art Unit: 1771

regard to claim 36, the '717 Patent teaches sterilizing by gamma radiation (column 11, lines 9-10).

With regard to claim 4, although Lucast et al. do not explicitly teach the limitation of the compression force generated by the backing material at an elongation of 20 to 70%, it is reasonable to presume that said limitations are inherent to the invention. Support for said presumption is found in the use of similar materials (i.e. polyester) and in the similar production steps (i.e. stitch-bonded nonwoven) used to produce the medical tape. The burden is upon the Applicant to prove otherwise. *In re Fitzgerald*, 205 USPQ 594. In the alternative, it would have been obvious to one having ordinary skill in the art to provide a compression force of from 0.2 N/cm to 10 N/cm at an elongation of from 20 to 70% in order to create a medical tape with the desired strength, elongation, and break properties that are known in the art to be adjustable.

With regard to claims 5 and 23, Lucast et al. do not disclose a basis weight for the backing material. It would have been obvious to a person having ordinary skill in the art to provide a stitch-bonded nonwoven with a basis weight of between 10 and 350 grams per square meter in order to make the tape with a usable rigidity desired in the field of medical tapes for use on human skin.

With regard to claims 10, 25, and 26, Although Lucast et al. do not explicitly teach the limitations of dynamic-complex glass transition temperatures at a frequency of 0.1 rad/s, it is reasonable to presume that said limitations are inherent to the invention. Support for said presumption is found in the use of similar materials (i.e. adhesive composition comprising styrene block copolymers) and in the similar production steps

Art Unit: 1771

(i.e. coating the adhesive on a stitch-bonded fabric) used to produce the medical tape. The burden is upon the Applicant to prove otherwise. *In re Fitzgerald*, 205 USPQ 594. In the alternative, it would have been obvious to one having ordinary skill in the art to use adhesive with the claimed glass transition temperatures in order to provide the optimal amount of tackiness for use as a medical tape.

With regard to claims 15, 27, and 28, Lucast et al. do not disclose the weight per unit area of the adhesive on the backing material. The amount of adhesive is a result effective variable that would affect the degree of adhesion the tape would have to the skin. It would have been obvious to one having ordinary skill in the art to provide between 130 and 500 grams per square meter of adhesive in order to create a medical tape with the optimum amount of adhesion property fit for its intended use on human skin, since it has been held that optimization of a result effective variable involves only routine skill in the art.

5. Claim 2 is rejected under 35 U.S.C. 103(a) as being unpatentable over Lucast et al. in view of Merkle et al. and the '717 Patent as applied to claim 1 above, and further in view of Wildeman et al. (U.S. Patent No. 3,967,472).

Lucast et al. do not disclose the stitches of the fabric to be formed from loops from the fibers of the web. Wildeman et al. disclose that stitch-bonded fabrics may be stitched with the loops from the web (column 3, lines 40-68). It would have been obvious to a person having ordinary skill in the art at the time of the invention to stitch the fabric of Lucast et al. with loops from the web in order to avoid using extra stitching thread, as taught by Wildeman et al.



Art Unit: 1771

6. Claim 6 is rejected under 35 U.S.C. 103(a) as being unpatentable over Lucast et al. in view of Merkle et al., the '717 Patent, and Koketsu et al. as applied to claim 1 above, and further in view of Bodenschatz et al. (U.S. Patent No. 6,074,965).

Lucast et al. do not teach reinforcing fibers in the nonwoven backing layer. Bodenschatz et al. teach a medical material that is supported with high-strength fibers with a maximum tensile strength over 60 cN/tex (Abstract). It would have been obvious to one having ordinary skill in the art to reinforce the stitch-bonded nonwoven web of Lucast et al. with high-strength fibers in order to create a tape with increased strength, as taught by Bodenschatz et al.

7. Claim 19 is rejected under 35 U.S.C. 103(a) as being unpatentable over Lucast et al. in view of Merkle et al., the '717 Patent, and Koketsu et al. as applied to claim 1 above, and further in view of Seabold et al. (U.S. Patent No. 4,315,047).

Lucast et al. do not disclose coating the backing material with metallic substances. Seabold et al. teach that adhesive tapes may be coated with metal vapor on the backside as a means of rendering the tape opaque (column 6, lines 65-68). It would have been obvious to one having ordinary skill in the art to add metal vapor to the backing of Lucast et al. in order to make the tape non-transparent, as taught by Seabold et al.

8. Claims 31 and 32 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lucast et al. in view of Merkle et al., the '717 Patent, and Koketsu et al. as applied to claim 1 above, and further in view of Kantner et al. (U.S. Patent No. 5,489,624).

Art Unit: 1771

Neither Lucast et al. nor Merkle et al. teach incorporating pharmacologically active agents as not in co-mixture with the adhesive. Kantner et al. teach that adhesive materials in the medical field can frequently be used to transport drugs through the skin (Abstract). Kantner et al. disclose several examples of biologically active material that would exist in particle form that can be incorporated into the adhesive (column 9, lines 28-41). It would have been obvious to a person having ordinary skill in the art at the time of the invention to incorporate active agents that are not in co-mixture with the adhesive composition in the medical tape of Lucast et al. in order to provide various healing properties to the tape, as taught by Kantner et al.

### ***Double Patenting***

9. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

10. Claims 1, 2, 4-8, 10-15, and 17-36 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-27

Art Unit: 1771

of U.S. Patent No. 6,555,730 to Albrod et al. in view of Merkle et al. (U.S. Patent No. 5,527,536).

Albrod et al. claims a backing material for medical purposes that is similar to the current application. Albrod et al. does not recite a pharmacologically active agent to be present in the adhesive. Merkle et al. disclose a medical patch for controlled release of pharmacologically active agents (Abstract). The adhesive comprises a block copolymer that comprises polystyrene for one block and a mixture of ethylene and butylenes for another block (Abstract). It would have been obvious to a person having ordinary skill in the art at the time of the invention to incorporate a pharmacologically active agent into the tape of Albrod et al. in order to provide the tape with an enhanced medical function, as taught by Merkle et al.

### ***Response to Arguments***

11. Applicant's arguments filed June 30, 2005 have been fully considered but they are not persuasive.

12. Applicant argues that the references fail to teach or suggest the yarns have water absorption of less than 30%. However, it is known in the art that synthetic yarns, in general possess that property. For purposes of the rejection, nylon is specifically shown to meet the claimed limitation.

### ***Conclusion***

Art Unit: 1771

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeremy R. Pierce whose telephone number is (571) 272-1479. The examiner can normally be reached on normal business hours, but works flextime hours.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Terrel Morris can be reached on (571) 272-1478. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

JRP  
Jeremy R. Pierce  
October 26, 2005

*Elizabeth M. Cole*  
ELIZABETH M. COLE  
PRIMARY EXAMINER